Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

PUBLISHED Tuesday, April 28, 2026 · anteris technologies pty ltd

AI BRIEFING

⬤ Anteris Technologies secures CMS reimbursement supporting U.S. site activation for the global pivotal PARADIGM Trial evaluating the DurAVR THV.
⬤ This development marks a significant milestone for the company's U.S. launch efforts.
⬤ The PARADIGM Trial is designed to assess the safety and efficacy of the DurAVR THV in treating heart failure patients.